Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease.

Abstract

To evaluate the effects of roxithromycin in patients with chronic lower respiratory tract disease including diffuse panbronchiolitis, we studied lymphocyte function-associated antigen-1 (LFA-1) and Mac-1, neutrophil adhesion molecules, using peripheral neutrophils from healthy volunteers and from patients with chronic lower respiratory tract disease. The number of Mac-1 expressed on neutrophils of the patients was significantly greater (0.68 +/- 0.16) than in the healthy subjects (0.45 +/- 0.14), while the number of LFA-1 expressed on neutrophils of the patients was nearly similar to that in the healthy volunteers (0.95 +/- 0.10 vs 0.89 +/- 0.11). The neutrophil numbers in bronchoalveolar lavage fluid and the number of Mac-1 expressed on peripheral neutrophils significantly decreased in all patients who responded clinically to a low dose of roxithromycin for a long period of time (56.0 +/- 25.2 vs. 22.7 +/- 19.7%, p < 0.05 and 0.70 +/- 0.16 vs. 0.59 +/- 0.08, p < 0.05, respectively), whereas roxithromycin had no effect on the quantitative expression of LFA-1 (0.96 +/- 0.14 to 1.00 +/- 0.09, not significant) in all responders.

• Authors: S Kusano, J Kadota, S Kohno, K Iida, K Kawakami, T Morikawa, K Hara
• Journal: Respiration; international review of thoracic diseases (Respiration) Vol. 62 Issue 4 Pg. 217-22 ( 1995) ISSN: 0025-7931 [Print] Switzerland
• PMID: 8578018 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Lymphocyte Function-Associated Antigen-1
• Macrophage-1 Antigen
• Roxithromycin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Bronchoalveolar Lavage Fluid (chemistry, cytology)
• Chronic Disease
• Humans
• Lymphocyte Function-Associated Antigen-1 (metabolism)
• Macrophage-1 Antigen (metabolism)
• Middle Aged
• Neutrophils (drug effects, metabolism)
• Reference Values
• Respiratory Tract Diseases (drug therapy, metabolism)
• Roxithromycin (therapeutic use)